We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 44% below its sector, cheaper than its peers on earnings.
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save PGHL.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
